December 9, 2014 by Val Kennedy
Spinal Modulation closes enrollment in a U.S. pivotal study of its Axium neurotransmitter system for the treatment of chronic pain.
Spinal Modulation said it completed enrollment in a U.S. pivotal study of its Axium neurotransmitter system for the treatment of chronic pain.
The Accurate study is slated to track 152 patients at 22 U.S. sites. Researchers are scheduled to present the clinical trial’s design at the upcoming annual meeting of the North American Neuromodulation Society, to be held in Las Vegas from Dec. 11 to 14. The company also plans to release clinical data at the meeting from studies conducted in Europe and Australia, where the device is already on the market, according to a press release.
Axium is an implantable device that transmits electrical pulses to mask or block pain signals to the brain. Axium differs from similar products because it targets the dorsal root ganglion of the spinal neural system, Spinal Modulation said.